
MIRZYME AWARDED THE FIRST FAST-TRACK INNOVATION PASSPORT FOR THE TREATMENT OF PREECLAMPSIA
MIRZYME THERAPEUTICS AWARDED THE FIRST FAST-TRACK INNOVATION PASSPORT FOR THE TREATMENT OF PREECLAMPSIA FROM THE MHRA, THE UK REGULATOR...
MirZyme has zero debt and is financed by equity. The company intends to progress each of its pipeline of patented products in a way that those that will generate income in the shorter term can finance the development of those that will take longer to bring to market.
MIRZYME AWARDED THE FIRST FAST-TRACK INNOVATION PASSPORT FOR THE TREATMENT OF PREECLAMPSIA
CEO Nominated for Businessman of The Year
Women’s Health Innovation Summit - Boston, USA
U.K. policy report sets out a vision to incentivise industry to develop pregnancy-specific medicines
ONE PILL WONDER – MirZyme Therapeutics on AIMDay at Oxford University
Women's Health Strategy: Call for Evidence
COVID-19 leads to preeclampsia and poor pregnancy outcomes
Saving the Lives of Mothers and Babies - Webinar
Two breakthrough studies show a hydrogen sulfide drug prevents preeclampsia
MirZyme Therapeutics partners with King Abdulaziz University
Scientists at MirZyme have developed a breakthrough ‘miracle’ cure for preeclampsia
Europe’s New Roadmap for a Healthier Pregnancy
The statin that saves babies from stillbirth
Breakthrough in fight against pre-eclampsia: Scientists may have found cause of the life-threatening